Agomelatine Treatment of Major Depressive Disorder in Parkinson's Disease: A Case Series

Major Depressive Disorder (MDD) is among the most frequent comorbidities occurring in the course of Parkinson’s disease (PD), and therefore, most PD patients receive antidepressant drugs. Agomelatine is a recently introduced antidepressant drug acting as an MT1/MT2 melatonergic receptor agonist and...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of Neuropsychiatry and Clinical Neurosciences Vol. 25; no. 4; pp. 343 - 345
Main Authors:	De Berardis, Domenico, Fornaro, Michele, Serroni, Nicola, Olivieri, Luigi, Marini, Stefano, Moschetta, Francesco Saverio, Srinivasan, Venkataramanujam, Assetta, Maurizio, Valchera, Alessandro, Salone, Anatolia, Martinotti, Giovanni, Onofrj, Marco, Di Giannantonio, Massimo
Format:	Journal Article
Language:	English
Published:	Arlington, VA American Psychiatric Association 01-10-2013 American Psychiatric Publishing American Psychiatric Publishing, Inc
Subjects:	Acetamides - therapeutic use Adult and adolescent clinical studies Antidepressive Agents - therapeutic use Biological and medical sciences Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Depression Depressive Disorder, Major - complications Depressive Disorder, Major - drug therapy Female Humans Male Medical sciences Middle Aged Miscellaneous Mood disorders Neurology Organic mental disorders. Neuropsychology Parkinson Disease - complications Parkinson Disease - drug therapy Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Mood disorder Melatonin Nervous system diseases Parkinson disease Depression Cerebral disorder Treatment Analog Central nervous system disease Degenerative disease Agomelatine Pineal hormone Extrapyramidal syndrome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Major Depressive Disorder (MDD) is among the most frequent comorbidities occurring in the course of Parkinson’s disease (PD), and therefore, most PD patients receive antidepressant drugs. Agomelatine is a recently introduced antidepressant drug acting as an MT1/MT2 melatonergic receptor agonist and 5HT2C/5HT2B serotonergic antagonist. The aim of this case series was to evaluate the role of agomelatine in the treatment of MDD associated with PD.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0895-0172 1545-7222
DOI:	10.1176/appi.neuropsych.12110286